Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

The two drug makers will jointly develop four diabetes drugs: two oral agents from Boehringer Ingelheim and two basal insulin analogues from Lilly.

You may also be interested in...



Deal Watch: Allergan Keeps After Hair Loss With Exicure Deal

Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.

Lilly and Boehringer Ingelheim Launch Biosimilar Lantus In UK, Germany

The cost of biosimilar Lantus to payers is at around a 15% discount to the originator product in the UK, but cost-savings are expected to vary across Europe as supply contracts with health insurers and hospitals are negotiated.

Merck And Pfizer Make A Late Play For The Diabetes Market

Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.

Related Content

Topics

UsernamePublicRestriction

Register

PS071682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel